GlassScriptPhysician profile
Stephanie F Freels
NPI 1952319303
$10,391.64
in general payments reported to CMS, 2019-2025
28 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,520 · 2020: $1,151 · 2021: $1,720 · 2022: $2,094 · 2023: $2,273 · 2024: $633.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,906.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,906.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,101.49 | 2019-2024 | |
| Abbvie INC. | $1,781.05 | 2019-2024 | |
| Sun Pharmaceutical Industries INC. | $1,233.64 | 2019-2024 | Absorica Ld, Winlevi, Ilumya |
| Dermavant Sciences, INC. | $779.07 | 2022-2024 | Vtama |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $732.99 | 2019-2023 | Arazlo, Jublia |
| Pfizer INC. | $545.05 | 2019-2024 | |
| Janssen Biotech, INC. | $515.58 | 2019-2024 | Tremfya, Simponi Aria, Simponi |
| Lilly USA, LLC | $368.98 | 2019-2023 | Taltz |
| Almirall LLC | $365.63 | 2019-2022 | |
| Galderma Laboratories, L.P. | $234.02 | 2019-2023 | |
| Incyte Corporation | $229.52 | 2022-2023 | Opzelura |
| Leo Pharma INC. | $228.56 | 2021-2023 | Adbry |
| Ucb, INC. | $179.31 | 2020-2024 | Bimzelx |
| E.R. Squibb & Sons, L.L.C. | $172.88 | 2022-2024 | Sotyktu |
| Amgen INC. | $161.67 | 2019-2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Epi Health, LLC | $151.35 | 2019-2022 | |
| Mayne Pharma Commercial LLC | $144.56 | 2019-2023 | |
| Vyne Pharmaceuticals INC. | $143.56 | 2020-2021 | |
| Arcutis Biotherapeutics, INC. | $62.83 | 2023-2024 | Zoryve |
| Encore Dermatology INC. | $48.21 | 2019 | |
| Dermira, INC. | $43.77 | 2019 | |
| Medimetriks Pharmaceuticals, INC. | $38.14 | 2020-2022 | |
| Allergan, INC. | $31.49 | 2019-2021 | |
| Sandoz INC. | $28.79 | 2023 | Hyrimoz |
| Regeneron Healthcare Solutions, INC. | $27.92 | 2021 | |
| Genzyme Corporation | $17.49 | 2020 | |
| Aclaris Therapeutics, INC. | $12.83 | 2019 | |
| Sebela Pharmaceuticals INC. | $11.26 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephanie Freels listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.